Stansky Michael P 4

What Happened

Michael P. Stansky, a director of TriSalus Life Sciences, was granted a derivative award covering 92,537 shares on February 4, 2026. The reported acquisition price is $0.00 per share (derivative award, Form 4 transaction code A). The award is subject to vesting rather than an immediate open-market purchase or sale, so there was no cash exchanged at grant.

Key Details

• Transaction date: 2026-02-04; Filing date: 2026-02-11 (filed 7 days after the transaction).
• Amount: 92,537 shares reported as a derivative award at $0.00 per share.
• Vesting: Shares vest in three equal annual installments beginning February 4, 2027, subject to continued service (per footnote).
• Shares owned after transaction: Not disclosed in the provided filing.
• Transaction type: Award/Grant (code A); this is not an immediate purchase or sale and does not indicate a current cash investment.

Context

This was a time-vesting derivative award (likely options or RSUs per the footnote) that will convert into shares over three years if the director remains in service. Because the award vests in the future, it does not reflect an immediate market transaction or sale; investors typically view grants as part of compensation rather than a direct bullish or bearish signal. The filing was submitted a week after the grant date; Form 4s are normally due within two business days, so the timing may be later than standard SEC reporting expectations.